EyePoint, Inc.
Key Metrics
- Previous Close
- $0.30
- 52-Week Range
- $0.27 – $19.11
- Market Cap
- $30.95M
- P/E (TTM)
- —
- EPS (TTM)
- -3.97
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.23
- PEG Ratio
- —
- Return on Equity
- -221.92%
- Return on Assets
- -105.25%
- Gross Margin
- 0.00%
- Operating Margin
- -13642.03%
- Profit Margin
- 0.00%
- Current Ratio
- 3.30
- Debt/Equity
- 0.20
- Total Debt
- $21.76M
- Free Cash Flow
- $-169.81M
- Revenue Growth
- -21.70%
- Earnings Growth
- —
- Enterprise Value
- $-65.51M
Market Snapshot
About
EyePoint Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing therapeutics for serious eye disorders. The company's proprietary Durasert technology platform enables sustained, controlled release of medication directly into the eye, providing long-term therapeutic effect from a single administration. EyePoint markets YUTIQ for chronic non-infectious uveitis and DEXYCU for post-surgical inflammation, while developing additional product candidates for retinal diseases including wet age-related macular degeneration and diabetic macular edema. The company's approach aims to reduce treatment burden for patients with chronic eye conditions.